 |
Prospector
Profile
08.0010
|
| |
| Integrated Pharmaceuticals, Inc. |
NAICS |
541710 |
| 310 Authority Drive
Fitchburg, MA 01420 |
Description |
Biotechnology |
| (978) 696-0020 |
Employees |
6 |
| http://www.intepharm.com/ |
Revenue |
(mil) |
0.0600 |
| |
Income |
(mil) |
-2.1400 |
| |
Assets |
(mil) |
2.4280 |
| |
Liability |
(mil) |
0.4040 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Integrated Pharmaceuticals, Inc. had a net loss of $329,630 for the three months ended September 30, 2007, much lower than the $502,647 net loss incurred during the three months ended September 30, 2006. For the nine months ended September 30, 2007, the Company had a $1,294,999 net loss, which is higher than the $1,565,592 net loss incurred during the nine months ended September 30, 2006. As a result of its recurring losses, the Company had an acccumulated deficit of $15,906,611 and only $866,429 in stockholders' equity.
|
| |
|
Intellectual Property:
The Company relies heavily on patents and trade secrets to protect production techniques. Currently, the Company is the exclusive licensee of two issued patents, U.S. patent nos. 6,416,981 and 6,828,130 relating to the production of gluconate derivatives; and a divisional patent application that broadens the protection with respect to gluconate derivatives. The issued patents are a key component of its business plan. Three of its directors, through their partnership, NEC Partnership, have entered into a license granting the Company the exclusive rights to these patents and non-exclusive rights to related trade secret information. The Company also owns eight US patent applications related to other aspects of its gluconate derivative technology, including applications relating to calcium supplement and dairy product. [SEC Filing 10-KSB 03-30-07]
|
| |
|
Description:
The Company engages in the development and production of specialty chemicals and nutraceuticals for the pharmaceutical, nutraceutical, and functional food industries.
|
| |
|
Officers:
Chinmay Chatterjee (Pres., CEO & Dir.); Nilu P. Chatterjee (VP, Treas. & Dir.); Edward D. Furtado (VP, Sec. & Dir.); David H. Smith (Dir.); Sally Johnson Chin (Dir.); Ken Wlosek (Dir.)
|
| |
|
Auditor:
Williams & Webster PS
|
| |
|
Securities:
Common Stock-Symbol INTP.OB; OTC BB;
40,975,328 common shares outstanding as of November 16, 2007.
|
| |
| |
| |
| return to main page |
|
|
